Patents Assigned to St. Vincent's Hospital Melbourne
-
Patent number: 9717446Abstract: A method for non-invasive determination of oxygen saturation of blood within a deep vascular structure of a human or animal patient comprising locating on skin of the patient in a vicinity of the deep vascular structure of interest emitter and receiver elements of a light oximeter device, wherein optimal location of said elements is achieved through matching of a plethysmography trace obtained from the oximeter device to known plethysmography characteristics of the deep vascular structure of interest, wherein the emitter element emits light at wavelengths of from about 1045 nm to about 1055 nm and from about 1085 nm to about 1095 nm, and wherein oxygen saturation is determined from a ratio of light absorbed at these two wavelengths by haemoglobin in blood within the vascular structure of interest.Type: GrantFiled: July 8, 2011Date of Patent: August 1, 2017Assignee: ST. VINCENT'S HOSPITAL (MELBOURNE) LIMITEDInventors: Barry Dixon, Paul Randall Stoddart
-
Publication number: 20130172703Abstract: A method for non-invasive determination of oxygen saturation of blood within a deep vascular structure of a human or animal patient comprising locating on skin of the patient in a vicinity of the deep vascular structure of interest emitter and receiver elements of a light oximeter device, wherein optimal location of said elements is achieved through matching of a plethysmography trace obtained from the oximeter device to known plethysmography characteristics of the deep vascular structure of interest, wherein the emitter element emits light at wavelengths of from about 1045 nm to about 1055 nm and from about 1085 nm to about 1095 nm, and wherein oxygen saturation is determined from a ratio of light absorbed at these two wave-lengths by haemoglobin in blood within the vascular structure of interest.Type: ApplicationFiled: July 8, 2011Publication date: July 4, 2013Applicant: St. Vincent's Hospital (Melbourne) LimitedInventors: Barry Dixon, Paul Randall Stoddart
-
Patent number: 8417305Abstract: The invention relates to a method for non-invasive determination of oxygen saturation of blood within a deep vascular structure of a human patient comprising locating on skin of the patient in a vicinity of the deep vascular structure of interest emitter and receiver elements of a light oximeter device, wherein optimal location of said elements is achieved through matching of a plethysmography trace obtained from the oximeter device to known plethysmography characteristics of the deep vascular structure of interest, and wherein oxygen saturation is determined from a ratio of light absorbed at different wavelengths by haemoglobin in the blood within the vascular structure of interest. The invention also relates to modified oximetry devices capable of carrying out the method.Type: GrantFiled: May 2, 2008Date of Patent: April 9, 2013Assignee: St. Vincents Hospital (Melbourne) LimitedInventor: Barry Dixon
-
Patent number: 8367317Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: December 23, 2010Date of Patent: February 5, 2013Assignee: Melbourne Health; St. Vincent's Hospital Melbourne; Austin HealthInventors: Angeline Ingrid Bartholomeusz, Stephen Logarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
-
Patent number: 8008000Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: December 30, 2008Date of Patent: August 30, 2011Assignees: Melbourne Health, Austin Health, Southern Health, Alfred Health, St. Vincent's Hospital MelbourneInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Lilly Ka Wai Yuen, Joseph John Sasadeusz
-
Patent number: 7887813Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: October 31, 2007Date of Patent: February 15, 2011Assignees: Melbourne Health, St. Vincent's Hospital Melbourne, Austin HealthInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
-
Patent number: 7875423Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: October 20, 2004Date of Patent: January 25, 2011Assignees: Melbourne Health, Austin Health, Southern Health, Alfred Health, St. Vincent's Hospital MelbourneInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Lilly Ka Wai Yuen, Joseph John Sasadeusz
-
Publication number: 20100075299Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.Type: ApplicationFiled: June 4, 2007Publication date: March 25, 2010Applicants: MELBOURNE HEALTH, AUSTIN HEALTH, BAYSIDE HEALTH, ST.VINCENT'S HOSPITAL (MELBOURNE) LTD. TRADING AS ST. VINCENT'S HOSPITAL MELBOURNE, SOUTHERN HEALTHInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayre, Lilly Ka Wai Yuen, Peter William Angus, Joseph John Sasadeusz, Paul Desmond, Hans Tillman, Thomas Bock, William Sievert, Sharon Lewin
-
Publication number: 20090155312Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: December 30, 2008Publication date: June 18, 2009Applicants: MELBOURNE HEALTH, AUSTIN HEALTH, SOUTHERN HEALTH, BAYSIDE HEALTH, ST. VINCENT'S HOSPITAL (MELBOURNE) LTD TRADING AS ST. VINCENT'S HOSPITAL MELBOURNEInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayers, Lilly Ka Wai Yuen, Joseph John Sasadeusz
-
Publication number: 20080176218Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: October 31, 2007Publication date: July 24, 2008Applicants: Melbourne Health, St. Vincent's Hospital (Melbourne) Ltd. trading as St. Vincent's Hospital Melbourne, Austin HealthInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus